Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI363 + XELOX in First-line Advanced Gastric/GEJ Cancer
NCT06610799Phase 1Recruiting
- Start
- Oct 2024
- Primary completion
- Jun 2025
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IBI363 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. Primary endpoints: Objective Response Rate up to 2 years and Disease Control Rate up to 2 years. Started Oct 2024; status: recruiting.
02
Drugs
IBI363
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06610799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06610799.